Diagnostics firm QuidelOrtho Corp is looking to sell its point-of-care testing unit at a valuation of $1.5 billion, the ...
Point-of-care testing is disrupting global diagnostics, creating opportunities for companies such as Lumos Diagnostics ...
Large scale deployment of rapid, low-cost, hand-held point of care testing devices for diagnosing infectious diseases is critical for improving global health. Recent advances in engineering and ...
QuidelOrtho (QDEL) is looking to sell its point-of-care testing unit at a $1.5B valuation, and private equity groups have already expressed interest in the transaction, The Financial Times reported on ...
The company’s focus on high accuracy POCT testing reagents aligns precisely with this demand, integrating robust quality control, innovative biochemistry, and user-centered design. Moreover, the ...
LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: ...
This presentation will briefly cover point-of-care testing (POCT) from a historical standpoint. (What are we doing and why did we decide to do it this way?) This presentation will incorporate ...
Instant diagnosis and treatment of potentially life-threatening Strep A infections is now very close to reality across Australia's remote and regional areas thanks to molecular point-of-care testing ...
NINGBO, ZHEJIANG, CHINA, February 3, 2026 /EINPresswire.com/ — Ningbo Qinmeng Maternal and Child Products Co., Ltd., a subsidiary of Ningbo Ciliang Import and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results